Zosano Pharma Corp Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-12-31: Form 8-K; Period of report 2015-12-31; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2015-11-19: Form 8-K; Period of report 2015-11-13; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2015-11-17: Form 8-K/A; Period of report 2015-11-16; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2015-11-16: Form 8-K; Period of report 2015-11-16; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-12-31 | 8-K | 2015-12-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As previously announced on September 8, 2015, Peter Daddona, Ph.D. retires from the position of Chief Scientific Officer (and Chief Scientific Officer of our wholly owned subsidiary ZP Opco, Inc., having served in that position since 2006), effective December 31, 2015 and the Company has entered into a Scientific Advisor Agreement with Dr. Daddona dated December 31, 2015 and effective January 1, 2016 (the “Agreement”). | d106332d8k.htm |
| 2015-11-19 | 8-K | 2015-11-13 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On November 13, 2015, we held an annual meeting of shareholders. | d72939d8k.htm |
| 2015-11-17 | 8-K/A | 2015-11-16 | 7.01 Regulation FD Disclosure | 7.01 A copy of the Company’s current investor presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. | d17014d8ka.htm |
| 2015-11-16 | 8-K | 2015-11-16 | 7.01 Regulation FD Disclosure | 7.01 A copy of the Company’s current investor presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. | d88978d8k.htm |
| 2015-11-09 | 8-K | 2015-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2015, Zosano Pharma Corporation issued a press release titled “Zosano Pharma Reports Third Quarter 2015 Financial Results.” The press release is furnished herewith as Exhibit 99.1. | d11006d8k.htm |
| 2015-09-29 | 8-K | 2015-09-29 | 7.01 Regulation FD Disclosure | 7.01 Our management will make a presentation at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015. | d24192d8k.htm |
| 2015-09-28 | 8-K | 2015-09-28 | 1.02 Termination of a Material Definitive Agreement | 1.02 On September 28, 2015, we terminated the Collaboration, Development and License Agreement dated as of November 21, 2014, or Collaboration Agreement, between Eli Lilly and Company, or Lilly, and our wholly owned subsidiary, ZP Opco, Inc. We terminated the Collaboration Agreement in accordance with its terms following our determination that it is commercially unreasonable to pursue one of the critical success factors under the Collaboration Agreement, relating to worldwide regulatory approval of Daily ZP-PTH by 2019. | d76505d8k.htm |
| 2015-09-08 | 8-K | 2015-09-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Konstantinos Alataris, Ph.D., has been appointed as our President and as President and Chief Operating Officer of our wholly owned subsidiary ZP Opco, Inc., effective September 21, 2015. | d61328d8k.htm |
| 2015-08-17 | 8-K | 2015-08-11 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d54759d8k.htm |
| 2015-08-12 | 8-K | 2015-08-12 | 2.02 Results of Operations and Financial Condition | 2.02 On August 12, 2015, Zosano Pharma Corporation issued a press release titled “Zosano Pharma Reports Second Quarter 2015 Financial Results.” The press release is furnished herewith as Exhibit 99.1. | d34248d8k.htm |
| 2015-07-06 | 8-K | 2015-07-02 | 8.01 Other Events | d72680d8k.htm | |
| 2015-06-29 | 8-K | 2015-06-23 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 On June 23, 2015, our wholly owned subsidiary, ZP Opco, Inc., entered into a First Amendment to Loan and Security Agreement with Hercules Technology Growth Capital, Inc. and Hercules Capital Funding Trust 2014-1. | d949285d8k.htm |
| 2015-06-09 | 8-K | 2015-06-09 | 7.01 Regulation FD Disclosure | 7.01 A copy of the Company’s current investor presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. | d939689d8k.htm |
| 2015-05-29 | 8-K | 2015-05-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 29, 2015, we entered into an amendment to our employment agreement with Peter Daddona, Ph.D., our Chief Scientific Officer. | d933903d8k.htm |
| 2015-05-27 | 8-K | 2015-05-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 22, 2015, our Board of Directors elected Joseph P. Hagan to our Board of Directors as a Class III director. | d933014d8k.htm |
| 2015-05-11 | 8-K | 2015-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2015, Zosano Pharma Corporation issued a press release titled “Zosano Pharma Reports First Quarter 2015 Financial Results.” The press release is furnished herewith as Exhibit 99.1. | d923509d8k.htm |
| 2015-05-01 | 8-K | 2015-04-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 We have hired Laxmi Peri as our Senior Vice President, Operations beginning April 27, 2015. 8.01 We have appointed Thorsten von Stein, M.D., Ph.D. as our Chief Medical Officer. | d918087d8k.htm |
| 2015-04-15 | 8-K | 2015-04-15 | 7.01 Regulation FD Disclosure | 7.01 A copy of the Company’s current investor presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. | d909210d8k.htm |
| 2015-03-25 | 8-K | 2015-03-25 | 2.02 Results of Operations and Financial Condition | 2.02 On March 25, 2015, Zosano Pharma Corporation (the “Company”) issued a press release titled “Zosano Pharma Reports 2014 Financial Results.” The press release is furnished herewith as Exhibit 99.1. | d895602d8k.htm |
| 2015-02-03 | 8-K | 2015-01-29 | 3.02 Unregistered Sales of Equity Securities; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 3.02 On January 30, 2015, Zosano Pharma Corporation (the “Company”) issued and sold 1,363,636 shares (the “Shares”) of its of common stock, $0.0001 par value per share (“Common Stock”), to Eli Lilly and Company (“Lilly”), pursuant to a Common Stock Purchase Agreement dated as of November 21, 2014 between the Company and Lilly (the “Purchase Agreement”), for an aggregate cash purchase price of $14,999,996. 5.03 On January 29, 2015, the Company’s amended and restated certificate of incorporation (the “Restated Charter”), in the form previously filed as Exhibit 3.4 to pre-effective Amendment No. 1 to the Company’s Registration Statement on Form S-1 (File No. 333-196983) (the “Registration Statement”), was filed with the Secretary of State of the State of Delaware and became effective. | d865122d8k.htm |